{
  "id": 3036988,
  "title": "InnoCare 1H 2026 presentation: revenue jumps 55%, shares fall 7%",
  "url": "https://urgent.news/2026/08/24/innocare-1h-2026-presentation-revenue-jumps-55-shares-fall-7",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-24T14:16:35.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/innocare-1h-2026-presentation-revenue-jumps-55-shares-fall-7-93CH-4873805"
  },
  "original_language": "en",
  "account": "On August 24, InnoCare Pharma (HKEX:9969, SSE:688428) released its first-half 2026 financial results, stating that it had returned to profitability and witnessed a significant increase in revenue growth across its portfolio. Although the company's revenue performance was robust, its shares saw a decline of 6.96%, closing at $27.54 per share. This drop suggested that investors had anticipated even higher results or were awaiting a potential revision of full-year guidance from management.\n\nThe biotech company, based in Hong Kong and Shanghai, reported total revenue of RMB 1,137.1 million for the six months ending June 30, a 55.5% increase compared to the same period in 2025. The company's net profit reached RMB 239.7 million, a stark contrast to the RMB 36 million loss reported in the first half of 2025. InnoCare maintained a substantial cash position of around RMB 8.4 billion, providing ample resources for its expanding clinical pipeline.\n\nThe company's turnaround was primarily attributed to strong sales of its drugs and improved operational efficiency. Drug sales grew by 43.2% year-over-year to RMB 918.1 million, accounting for around 81% of the company's total revenue. The remaining revenue came from business development milestone payments and service revenue. InnoCare's return to profitability marked a significant milestone for the company, transitioning it from a development-stage biotech to a commercial-stage pharmaceutical company with three marketed products.",
  "summary": null,
  "key_points": [
    "InnoCare Pharma's revenue jumped 55% in H1 2026",
    "Shares fell 7% after results, investors expected more",
    "Net profit reached RMB 239.7 million, from RMB 36 million loss"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}